Sydney M Crago

This trial is testing tinlarebant, a novel oral therapy which is intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA).

The fellowship is a one-year program that will provide comprehensive training to residency graduates in the latest advancements in ophthalmology, including diagnostic and therapeutic techniques, surgical procedures and clinical research.

The company announced the Complete Response Letter from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”